Evidence for the Role of Luteinizing Hormone in Alzheimer Disease

Author(s): Kate M. Webber, Gemma Casadesus, Richard L. Bowen, George Perry, Mark A. Smith

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 7 , Issue 4 , 2007

Become EABM
Become Reviewer
Call for Editor


Epidemiological and experimental data supporting a role for luteinizing hormone in Alzheimer disease is accumulating. Paralleling the female predominance for developing Alzheimer disease, luteinizing hormone levels are significantly higher in females as compared to males and luteinizing hormone levels are higher still in individuals who succumb to Alzheimer disease. Importantly, luteinizing hormone, which is capable of modulating cognitive behavior, is not only present in the brain, but also has the highest receptor levels in the hippocampus, a key processor of cognition that is severely deteriorated in Alzheimer disease. These findings, together with data indicating that luteinizing hormone modulates amyloid-β protein precursor processing in vivo and in vitro, suggests that luteinizing hormone may contribute to Alzheimer disease pathology through an amyloid-dependent mechanism. Indeed, abolishing luteinizing hormone, using a potent gonadotropin-lowering agent, leuprolide acetate, in the amyloid-β protein precursor transgenic mice improved hippocampally- related cognitive performance and decreased amyloid-β deposition. These promising findings support the importance of luteinizing hormone in Alzheimer disease and bring to the forefront an alternative, and much needed therapeutic avenue for the treatment of this insidious disease.

Keywords: Alzheimer disease, amyloid-β, cognition, luteinizing hormone, leuprolide acetate, treatment

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [300 - 303]
Pages: 4
DOI: 10.2174/187153007782794326
Price: $65

Article Metrics

PDF: 8